1-10 of 10
Alessandra Ferrajoli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Katrien Van Roosbroeck, Francesca Fanini, Tetsuro Setoyama, Cristina Ivan, Cristian Rodriguez-Aguayo, Enrique Fuentes-Mattei, Lianchun Xiao, Ivan Vannini, Roxana S. Redis, Lucilla D'Abundo, Xinna Zhang, Milena S. Nicoloso, Simona Rossi, Vianey Gonzalez-Villasana, Rajesha Rupaimoole, Manuela Ferracin, Fortunato Morabito, Antonino Neri, Peter P. Ruvolo, Vivian R. Ruvolo, Chad V. Pecot, Dino Amadori, Lynne Abruzzo, Steliana Calin, Xuemei Wang, M. James You, Alessandra Ferrajoli, Robert Orlowski, William Plunkett, Tara M. Lichtenberg, Ramana V. Davuluri, Ioana Berindan-Neagoe, Massimo Negrini, Ignacio I. Wistuba, Hagop M. Kantarjian, Anil K. Sood, Gabriel Lopez-Berestein, Michael J. Keating, Muller Fabbri, George A. Calin
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11): 2891–2904.
https://doi.org/10.1158/1078-0432.CCR-16-1025
Published: 31 May 2017
View article titled, Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
Open the PDF for Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers in another window
Includes: Supplementary data
Journal Articles

Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia

Preetesh Jain, Michael J. Keating, William G. Wierda, Mariela Sivina, Philip A. Thompson, Alessandra Ferrajoli, Zeev Estrov, Hagop Kantarjian, Susan O'Brien, Jan A. Burger
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (9): 2154–2158.
https://doi.org/10.1158/1078-0432.CCR-16-1948
Published: 30 April 2017
View article titled, Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
Open the PDF for Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Candida Vitale, Lorenzo Falchi, Elisa ten Hacken, Hui Gao, Hila Shaim, Katrien Van Roosbroeck, George Calin, Susan O'Brien, Stefan Faderl, Xuemei Wang, William G. Wierda, Katayoun Rezvani, James M. Reuben, Jan A. Burger, Michael J. Keating, Alessandra Ferrajoli
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2359–2367.
https://doi.org/10.1158/1078-0432.CCR-15-2476
Published: 12 May 2016
View article titled, Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
Open the PDF for Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics in another window
Includes: Supplementary data
Journal Articles

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

Karen W.L. Yee, Zhihong Zeng, Marina Konopleva, Srdan Verstovsek, Farhad Ravandi, Alessandra Ferrajoli, Deborah Thomas, William Wierda, Efrosyni Apostolidou, Maher Albitar, Susan O'Brien, Michael Andreeff, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5165–5173.
https://doi.org/10.1158/1078-0432.CCR-06-0764
Published: 01 September 2006
View article titled, Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies in another window
Journal Articles

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

Francis Giles, Srdan Verstovsek, Deborah Thomas, Stanton Gerson, Jorge Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven Kornblau, Guillermo Garcia-Manero, Elias Jabbour, Susan O'Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7817–7824.
https://doi.org/10.1158/1078-0432.CCR-05-1070
Published: 08 November 2005
View article titled, Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Open the PDF for Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia in another window
Journal Articles

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Karen W.L. Yee, Anne Hagey, Srdan Verstovsek, Jorge Cortes, Guillermo Garcia-Manero, Susan M. O'Brien, Stefan Faderl, Deborah Thomas, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Maher Albitar, Evelyn McKeegan, David R. Grimm, Toby Mueller, Rhonda R. Holley-Shanks, Leonardo Sahelijo, Gary B. Gordon, Hagop M. Kantarjian, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6615–6624.
https://doi.org/10.1158/1078-0432.CCR-05-0650
Published: 15 September 2005
View article titled, Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies
Open the PDF for Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies in another window
Journal Articles

A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia

Francis Giles, Deborah Thomas, Guillermo Garcia-Manero, Stefan Faderl, Jorge Cortes, Srdan Verstovsek, Alessandra Ferrajoli, Sima Jeha, Miloslav Beran, Charles Koller, Michael Andreeff, Ann Cahill, Caroline Clairmont, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (9): 2908–2917.
https://doi.org/10.1158/1078-0432.CCR-03-0738
Published: 06 May 2004
View article titled, A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia
Open the PDF for A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia in another window
Journal Articles

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls

Hagop Kantarjian, Susan O’Brien, Jorge Cortes, Francis Giles, Jianqin Shan, Mary Beth Rios, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Michael Keating, Moshe Talpaz
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 68–75.
https://doi.org/10.1158/1078-0432.CCR-1035-3
Published: 20 January 2004
View article titled, Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls
Open the PDF for Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls in another window
Journal Articles

Development of Varicella-Zoster Virus Infection in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate

Gloria N. Mattiuzzi, Jorge E. Cortes, Moshe Talpaz, James Reuben, Mary Beth Rios, Jianjin Shan, Dimitrios Kontoyiannis, Francis J. Giles, Issam Raad, Srdan Verstovsek, Alessandra Ferrajoli, Hagop M. Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (3): 976–980.
Published: 01 March 2003
View article titled, Development of Varicella-Zoster Virus Infection in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate
Open the PDF for Development of Varicella-Zoster Virus Infection in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate in another window
Journal Articles

High Levels of Vascular Endothelial Growth Factor Receptor-2 Correlate with Shortened Survival in Chronic Lymphocytic Leukemia

Alessandra Ferrajoli, Taghi Manshouri, Zeev Estrov, Michael J. Keating, Susan O’Brien, Susan Lerner, Miloslav Beran, Hagop M. Kantarjian, Emil J. Freireich, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (4): 795–799.
Published: 01 April 2001
View article titled, High Levels of Vascular Endothelial Growth Factor Receptor-2 Correlate with Shortened Survival in Chronic Lymphocytic Leukemia
Open the PDF for High Levels of Vascular Endothelial Growth Factor Receptor-2 Correlate with Shortened Survival in Chronic Lymphocytic Leukemia in another window